SLC5A2 and diabetic kidney disease: Current drug therapies aim at retarding the disease progression through the blocking of either the renin-angiotensin system driving the vasoconstriction in hypertensive nephropathies or of the glucose reabsorption via sodium-glucose transporter 2 (SGLT2) inhibitors to lower the glycemia in Diabetic Kidney Disease (DKD) [10].